文献速递消化系统肿瘤

氟尿嘧啶、亚叶酸钙和伊立替康联合西妥昔单抗对比西妥昔单抗单药用于RAS和BRAF野生型转移性结直肠癌一线治疗后的维持治疗:III期ERMES研究

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study.
PubMed 文献 · J Clin Oncol · 2024-01-05

ERMES研究为多中心开放标签III期试验,入组未经治疗的RAS/BRAF野生型转移性结直肠癌患者,随机接受FOLFIRI/Cet持续治疗(A组)或FOLFIRI/Cet 8周期后西妥昔单抗单药维持(B组)。主要终点为改良符合方案人群的无进展生存非劣效性和B组G3-4不良事件发生率降低;结果显示B组未达到非劣效,但维持期G3-4不良事件较低(20.2% vs 35.1%)。

要点

  • B组未达到无进展生存非劣效:改良符合方案人群PFS 10 vs 12.2个月(非劣效P=0.43)。
  • B组维持期G3-4不良事件发生率为20.2%,低于A组的35.1%。
  • 诱导后西妥昔单抗单药维持不能推荐用于所有患者,但可在特定病例中考虑。

核心结论

  • ERMES研究未证明西妥昔单抗单药维持的非劣效性,尽管安全性更优,但诱导后单药西妥昔单抗维持不能推荐用于所有患者,可在特定病例中考虑。

研究设计与样本

  • 多中心、开放标签、III期试验,共随机分配606例未经治疗的RAS/BRAF野生型转移性结直肠癌患者,A组300例接受FOLFIRI/Cet直至疾病进展,B组306例接受FOLFIRI/Cet 8周期后西妥昔单抗单药维持。
  • 共同主要终点为改良符合方案人群(>8周期)的无进展生存非劣效性和B组对比A组的G3-4不良事件发生率降低。

主要发现

  • 中位随访22.3个月,改良符合方案人群共发生291例事件,B组对比A组的中位PFS为10 vs 12.2个月(非劣效P=0.43)。
  • 意向治疗人群(至少1周期)共发生503例事件,B组对比A组的中位PFS为9 vs 10.7个月(P=0.39)。
  • 改良符合方案人群的总生存B组对比A组为35.7 vs 30.7个月(P=0.119),意向治疗人群为31.0 vs 25.2个月(P=0.32)。
  • 维持治疗期间B组G3-4不良事件发生率为20.2%,低于A组的35.1%。

临床怎么用

  • 作者认为,诱导后单药西妥昔单抗维持不能推荐用于所有患者,但可在特定病例中作为选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The intensity of anti-EGFR-based first-line therapy for RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC), once disease control is achieved, is controversial. A de-escalation strategy with anti-EGFR monotherapy represents a potential option to maintain efficacy while reducing cytotoxicity. METHODS: In this multicenter, open-label, phase III trial, patients with untreated RAS/BRAF wt mCRC were randomly assigned to receive either fluorouracil, leucovorin, and irinotecan/cetuximab (FOLFIRI/Cet) until disease progression (arm A) or FOLFIRI/Cet for eight cycles followed by Cet alone (arm B). The coprimary end points were a noninferior progression-free survival (PFS) in the modified per-protocol (mPP) population (>eight cycles) and a lower incidence of grade (G) 3-4 adverse events (AEs) for arm B compared with arm A. RESULTS: Overall, 606 patients were randomly assigned, with 300 assigned to arm A and 306 to arm B. The median follow-up was 22.3 months. In the mPP population, 291 events occurred with a PFS of 10 versus 12.2 months for arms B and A, respectively (P of noninferiority = .43). In the intention-to-treatment (ITT, ≥one cycle) population, 503 events occurred with a PFS of 9 versus 10.7 months (P = .39). The overall survival was 35.7 versus 30.7 months (P = .119) and 31.0 versus 25.2 months (P = .32) in the mPP and ITT population, respectively. Arm B had lower G3-4 AEs during the maintenance period than arm A (20.2% v 35.1%). CONCLUSION: The ERMES study did not demonstrate noninferiority of maintenance with Cet alone. Despite a more favorable safety profile, maintenance with single-agent Cet after induction with FOLFIRI/Cet cannot be recommended for all patients but could represent an option in selected cases.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Pinto C, Orlandi A, Normanno N, et al. Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study. J Clin Oncol. 2024. PMID: 38181312. doi:10.1200/JCO.23.01021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。